Patients with prostatic hyperplasia who have more than one significant organ comorbidity, including heart, brain, lung, liver and kidney, are clinically referred to as high-risk patients. Although the use of a receptor blockers and 5
a reductase inhibitors have been used to spare some patients from surgery, there is still a proportion with poor outcomes and surgery is the most effective approach. Transurethral electrodesiccation of the prostate has been widely used as the gold standard for prostatic hyperplasia surgery. Adequate preoperative examination and appropriate individualized treatment for different comorbidities are done. For patients with hypertension, control blood pressure below 160/100 mm Hg; 2. For patients with cardiac insufficiency, reduce cardiac load, diuresis, vasodilation and increase cardiac contractility to improve cardiac function above class II; 3. For sinus bradycardia with positive atropine and isoprenaline excitation test or II AV block, a temporary cardiac pacemaker must be installed before surgery to survive the perioperative period; 4. For diabetic patients, control blood glucose <11,1 mmol/L; 5. For pulmonary diseases, control pulmonary infections, calm asthma and antispasmodic treatment to improve pulmonary ventilation; 6. The patient with urinary tract infection should have a urine culture and choose antibiotics according to the sensitive drugs to control the infection; 8, liver protection therapy for those with abnormal liver function; 9, stop using anticoagulant drugs (aspirin, Poliovel, etc.) for at least 1 week before surgery. The treatment of high-risk prostate hyperplasia with transurethral electrodes has high safety, less trauma, faster recovery, fewer complications and shorter hospital stay, which is a more ideal surgical procedure and broadens the surgical indications for prostate hyperplasia.